null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.01x Total Debt / Equity (Conservative)

Variable-rate debt on ~$1.8B term loan means 20bps rise adds ~$3.6M annual interest expense, compressing already thin ~8% EBITDA margins by ~0.2pp

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

India (largest CRO lab/talent hub) and China (clinical trial site access and bioanalytical reagent sourcing) are top geopolitical chokepoints

Top three international markets—EU (EUR), UK (GBP), Japan (JPY)—represent ~40% of revenue; EUR/USD and GBP/USD volatility poses ~2-4% revenue translation risk annually

Operations in 90+ countries; EUR, GBP, and JPY exposure collectively ~40% of revenue with meaningful devaluation risk given dollar-denominated debt obligations

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of input costs; however, lab consumables and specialized CRO software (e.g., Medidata/Veeva) create moderate non-substitutable dependency

Cloud termination risk is moderate; clinical data management and bioanalytical systems are partially on-premise or hybrid, migration would take 6-12 months but not catastrophic

Secondary tech stack (e.g., eClinical platforms, LIMS) is mostly SaaS from specialized vendors; AWS/Azure termination would disrupt data hosting but workarounds exist within 60-90 days

High API coupling risk to eClinical platforms (Medidata Rave, Veeva Vault); sponsor-mandated platform requirements mean Fortrea has limited unilateral switching ability

Near-zero Howey Test risk; revenue model is fee-for-service clinical research outsourcing—no investment contracts, profit-sharing, or token-based revenue components

Very High

High GDPR/CCPA exposure given patient-level clinical trial data across EU and US; Fortrea must comply with FDA 21 CFR Part 11, EMA, and cross-border data transfer regulations

Low-to-moderate; CRO market is competitive (ICON, Labcorp, IQVIA, PPD); no dominant market share position triggering merger review or monopolization concern

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~85-90% recurring via multi-year clinical trial contracts and FSP retainers; ~10-15% transactional (standalone lab work, early-phase projects)

Fee-for-service clinical outsourcing with milestone-based billings and FSP (functional service provider) retainer contracts as primary monetization vectors

Cost-plus with negotiated fixed-fee or unit-rate contracts; limited pass-through flexibility under inflationary pressure; sponsor pushback on rate increases above 3-5% annually

Moderate (6/10); sponsor concentration and competitive CRO market limit pricing power despite high switching costs once a trial is underway

Gross margin ~25-30%; EBITDA margin ~8-12%; below CRO peers like ICON (~15% EBITDA) due to post-spin cost structure and debt burden

No free-rider problem; services are bespoke and contracted. Churn risk stems from sponsor in-sourcing or competitor wins at contract renewal, estimated ~10-15% annual backlog attrition

Revenue growth is largely headcount-linear for clinical operations; ~65-70% of costs are labor; doubling revenue requires near-proportional CRA/staff scaling with modest leverage in tech roles

Sublinear only at FSP/tech-enabled segments; core clinical operations remain headcount-linear; marginal EBITDA improvement modest (~50-100bps per 10% revenue growth)

Not applicable; Fortrea is not a franchise model

At 10x scale, CAC would likely remain relationship-driven (BD teams, therapeutic expertise); unit economics improve modestly via therapeutic center-of-excellence leverage

Weak network effects; proprietary data assets and therapeutic expertise create soft moats but no traditional platform network effect; durability rating ~3/10

-36.2% Return on Assets (Negative equity)

Tier 2 (moderately recession-resistant); pharma R&D spending is relatively inelastic but biotech sponsor funding dries up in downturns, pressuring early-phase pipeline

Large pharmaceutical and biotechnology companies (top 20 pharma represent estimated ~40-50% of revenue)

Mid-size and emerging biotech sponsors (~30-35% of revenue); more volatile and funding-sensitive than large pharma

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being maintained for legacy lab infrastructure with limited reallocation to future-state digital/AI tools; CapEx ~2-3% of revenue, constrained by post-spin debt service obligations

0001965040

FTRE